 CAMBRIDGE, Mass.--BUSINESS WIRE--VBI Vaccines Inc. Nasdaq: VBIV VBI, a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported that the American Medical Association AMA Current Procedural Terminology CPT Panel has established a unique CPT code for a 3-antigen S, Pre-S1, Pre-S2 Hepatitis B HBV vaccine. If approved, VBIs 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from 